Form 4: Kyverna Therapeutics Director Daniel Spiegelman Granted Equity Awards

Kyverna Therapeutics, Inc. Director Daniel K. Spiegelman was granted 16,634 shares of common stock as restricted stock units and options to purchase 65,351 shares of common stock.

Summary

• Daniel K. Spiegelman, a Director of Kyverna Therapeutics, Inc. (KYTX), was granted equity awards on May 29, 2025.
• The awards include 16,634 shares of common stock in the form of a restricted stock unit (RSU) award, with a transaction price of $0.
• Additionally, Mr. Spiegelman received stock options to acquire 65,351 shares of common stock at an exercise price of $2.63 per share.
• Both the RSU award and the stock options are subject to vesting, which will occur in full on the earlier of May 29, 2026, or immediately prior to the Issuer's 2026 annual meeting of stockholders.
• Vesting is contingent upon Mr. Spiegelman's continuous service to Kyverna Therapeutics, Inc. through the applicable vesting date.
• The stock options have an expiration date of May 29, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation disclosure, not indicative of significant operational changes.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for attracting and retaining experienced board members.

Future Outlook

The equity awards granted to Director Daniel K. Spiegelman are structured to vest on the earlier of May 29, 2026, or immediately prior to the Issuer's 2026 annual meeting of stockholders, contingent on his continuous service, indicating a forward-looking incentive for his continued contribution to the company.

Industry Context

The granting of equity awards, such as restricted stock units and stock options, to directors is a common and widely accepted practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to align the interests of board members with those of shareholders, encouraging long-term strategic decision-making and value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for director compensation is a standard practice in the biotechnology sector, comparable to compensation structures at companies like Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity to incentivize and retain key personnel.
• The vesting schedule, tied to a specific future date or the next annual meeting, is also a common mechanism to ensure continued service and commitment, aligning with corporate governance best practices observed in publicly traded companies globally.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity awards to Daniel K. Spiegelman, a director of Kyverna Therapeutics, Inc., which constitutes a related party transaction as it is compensation provided to an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's incentives with shareholder value creation, potentially leading to more favorable long-term strategic decisions.
• Employees: While not directly impacted, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted stock units and stock options are expected to vest on the earlier of May 29, 2026, or immediately prior to the Issuer's 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Kyverna Therapeutics, KYTX, Form 4, Insider Transaction, Director Compensation, Equity Grant, Restricted Stock Unit, Stock Option, Beneficial Ownership